Tuesday, June 18, 2019

08:30 – 17:10
Auditorium (USI Università)
CLOSED WORKSHOP - BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE
Co-chairs: D. Rossi, Bellinzona (Switzerland), W.H. Wilson, Bethesda, MD (USA) and E. Zucca, Bellinzona (Switzerland)
Organized in co-operation with the American Association for Cancer Research – AACR and the European School of Oncology – ESO and with the endorsement of the Leukemia & Lymphoma Society - LLS by invitation only

15:00 – 17:15
Aula Magna (USI Università)
WORKSHOP – NEW GUIDELINES FROM THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP - ILROG
Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG
open to all 15-ICML attendees

PART 1 – NEW GUIDELINES FROM ILROG
Chair: L. Specht, Copenhagen (Denmark)

15:00
RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
A. Ng, Boston, MA (USA)

15:15
SOLITARY PLASMACYTOMA AND MULTIPLE MYELOMA
R. Tsang, Toronto (Canada)

15:30
IMAGING IN RADIATION THERAPY FOR LYMPHOMA
G. Mikhaeel, London (UK)

15:45
PROTON THERAPY FOR MEDIASTINAL LYMPHOMAS
B.S. Dabaja, Houston, TX (USA)

16:00
DISCUSSION

16:15
COFFEE BREAK inside Aula Magna (USI Università), for attendees

PART 2 – PANEL DISCUSSION
Led by J. Plastaras, Philadelphia, PA (USA)

16:30
FUTURE GUIDELINES TO BE DEVELOPED; ISSUES TO BE CONSIDERED IN ILROG GUIDELINES

16:50
HOW TO DISSEMINATE AND USE ILROG GUIDELINES
**Wednesday, June 19, 2019**

08:30 – 09:15  
**Article Nr**  
"MEET THE PROFESSOR" SESSIONS 📚  
5 parallel sessions

Room A  
EB09  
MISCELLANEOUS: EVERY YEAR A NEW STANDARD?  
S.V. Rajkumar, Rochester, MN (USA)  
repeated on Thursday, June 20, in Room B

Room B  
EB10  
THE MODERN APPROACH TO MANTLE CELL LYMPHOMA  
S. Rule, Plymouth (UK)  
repeated on Thursday, June 20, in Room A

Cinema Corso  
EB07  
MANAGING THE TOXICITIES OF CAR T-CELL THERAPY  
S.S. Neelapu, Houston, TX (USA)  
repeated on Friday, June 21, in Auditorium (USI Università)

Auditorium (USI Università)  
EB01  
PCNSL, A CURABLE DISEASE  
T.T. Batchelor, Boston, MA (USA)  
repeated on Thursday, June 20, in Cinema Corso

Aula Magna (USI Università)  
EB12  
WHAT WE SHOULD KNOW ABOUT NK/T-CELL LYMPHOMAS  
W. Zhao, Shanghai (China)  
offered only once

09:00 – 12:00  
**POSTER SESSION SET UP**

Marquee

09:30 – 10:15  
5 parallel sessions

Room A  
EB02  
DOUBLE HIT LYMPHOMA, SO WHAT?  
A. Davies, Southampton (UK)  
repeated on Friday, June 21, in Room B

Room B  
EB05  
HOW TO APPROACH CLL IN CLINICAL PRACTICE  
M. Hallek, Cologne (Germany)  
repeated on Friday, June 21, in Room A

Cinema Corso  
EB11  
LIQUID BIOPSY IN NON-HODGKIN’S LYMPHOMA  
W.H. Wilson, Bethesda, MD (USA)  
repeated on Thursday, June 20, in Auditorium (USI Università)

Auditorium (USI Università)  
EB06  
CUTANEOUS LYMPHOMAS  
W. Kempf, Zurich (Switzerland)  
repeated on Friday, June 21, in Cinema Corso

Aula Magna (USI Università)  
EB03  
BREAST IMPLANT ASSOCIATED ALC1 AND OTHER RARE T-CELL LYMPHOMAS  
L. de Leval, Lausanne (Switzerland)  
offered only once

10:15 – 10:35  
**COFFEE BREAK**

Marquee, Cinema Corso, USI Università
10:35 – 12:00
EDUCATIONAL SYMPOSIA
2 parallel sessions

Room A, Cinema Corso, Auditorium and Aula Magna (USI Università)

TREATING HODGKIN LYMPHOMA IN THE NEW MILLENNIUM
Chair: A. Engert, Cologne (Germany)

EB13 OPTIONS FOR FIRST LINE THERAPY OF HODGKIN LYMPHOMA
P.W.M. Johnson, Southampton (UK)

EB14 RELAPSED AND REFRACTORY DISEASE
A.S. LaCasce, Boston, MA (USA)

EB15 TREATMENT OF ELDERLY HODGKIN LYMPHOMA PATIENTS
A. Engert, Cologne (Germany)

Room B and Marquee

NEW DRUGS FOR NON-HODGKIN LYMPHOMA: BEYOND CHEMOTHERAPY
Chair: G. Salles, Lyon (France)

EB16 CAR T CELL THERAPY: FULL SPEED AHEAD
R.J. Brentjens, New York, NY (USA)

EB17 NEW DRUGS FOR OLD TARGETS
G. Salles, Lyon (France)

EB18 NEW DRUGS FOR NEW TARGETS
A. Younes, New York, NY (USA)

12:00 – 17:00
Abstract Nr

MARQUEE

POSTER SESSION

136 - 159 BIOLOGY AND PATHOLOGY
160 - 169 CLL
170 - 183 INDOLENT LYMPHOMAS
184 - 191 MANTLE CELL LYMPHOMAS
192 - 206 AGGRESSIVE LYMPHOMAS
207 - 217 EXTRANODAL LYMPHOMAS
218 - 233 PTCL AND NK/T CELL LYMPHOMAS
234 - 245 HODGKIN LYMPHOMAS
246 - 262 IMMUNOTHERAPY
263 - 285 NOVEL TREATMENTS

12:00 – 13:00
MARQUEE

LUNCH TIME AND POSTER VIEWING

13:00 – 14:00
ROOM A, B, MARQUEE, CINEMA CORSO, AUDITORIUM AND AULA MAGNA (USI UNIVERSITA)

OPENING OF THE CONFERENCE
WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona (Switzerland)

HENRY KAPLAN MEMORIAL LECTURE AND SAN SALVATORE FOUNDATION PRIZE
Introduction to San Salvatore Foundation: S. Coduri, Lugano (Switzerland)
Laudatio: R. Stahel, Zurich (Switzerland)

001 NEXT GENERATION CAR T CELLS FOR LYMPHOMA AND BEYOND
C.H. June, Philadelphia, PA (USA)

14:00 – 15:25
ROOM A, B, MARQUEE, CINEMA CORSO, AUDITORIUM AND AULA MAGNA (USI UNIVERSITA)

PLENARY SESSION
Co-chairs: J.O. Armitage, Omaha, NE (USA) and F. Cavalli, Bellinzona (Switzerland)
14:00 004 IDENTIFYING MUTATIONS ENRICHED IN RELAPSED-REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE
C. Rushton, Burnaby, B.C (Canada)

14:15 005 ROBUST: FIRST REPORT OF PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP (R2-CHOP) VS PLACEBO/R-CHOP IN PREVIOUSLY UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA
U. Vitolo, Turin (Italy)

14:30 006 ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP
G.S. Nowakowski, Rochester, MN (USA)

14:45 Discussant for presentations 004, 005 and 006: M.A. Shipp, Boston, MA (USA)

15:00 007 IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL
P. Langerbeins, Cologne (Germany)

15:15 Discussant for presentation 007: S.M. O’Brien, Irvine, CA (USA)

15:25 – 15:50 COFFEE BREAK
Marquee

15:50 – 16:50 NCCR-ICML JOINT SESSION - THE ROLE OF NON-CLINICAL MODELS AS BRIDGES TO EARLY CLINICAL TRIALS
Co-chairs: M. Foti, Philadelphia, PA (USA) and B. Nadel, Marseille (France)

15:50 008 DESIGNER ORGANOIDs FOR MODELING EPIGENETICS, SIGNALING, AND THERAPIES IN LYMPHOMA
A. Singh, New York, NY (USA)

16:10 009 MOUSE PDX AS NON-CLINICAL MODELS FOR LYMPHOMA
A. Louissaint, Boston, MA (USA)

16:30 010 ADVANCING OUR UNDERSTANDING AND TREATMENT OF LYMPHOMA WITH SPONTANEOUS CANINE MODELS
L. Aresu, Turin (Italy)

17:05 – 18:05 “FOCUS ON…” SESSIONS
5 parallel sessions

Room A

17:05 011 COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL
P. Jain, Houston, TX (USA)

17:15 012 IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL)
M. Wang, Houston, TX (USA)
AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA
A. Zoellner, Munich (Germany)

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY
S. Le Gouill, Nantes (France)

ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Y. Song, Beijing (China)

OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY
C. Visco, Verona (Italy)

PET IMAGING
Chair: B.D. Cheson, Washington, D.C. (USA)

A GENE EXPRESSION-BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD
B. Donati, Reggio Emilia (Italy)

PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)-POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION
M. Novo, Rochester, MN (USA)

HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY
L. Vercellino, Paris (France)

BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL
M. Trněný, Prague (Czech Republic)

RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY
S. Chauvie, Cuneo (Italy)

PROGNOSTIC VALUE OF PRE-TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY
P. Strati, Houston, TX (USA)

NON-HODGKIN LYMPHOMA IN ADOLESCENT AND YOUNG ADULTS - A NATIONAL PROSPECTIVE POPULATION-BASED STUDY
R. Carr, London (UK)
INCLUSION OF A PEDIATRIC PERSPECTIVE INTO RECOMMENDATIONS FOR THE INITIAL EVALUATION AND STAGING OF HODGKIN LYMPHOMA: A CALL TO ACTION FROM THE INTERNATIONAL SEARCH WORKING GROUP
J. Flerlage, Memphis, TN (USA)

SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
J. Flerlage, Memphis, TN (USA)

RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES
K. M. Kelly, Buffalo, NY (USA)

IBRUTINIB + CHEMOIMMUNOTHERAPY (CIT) FOR RELAPSED/REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL) IN CHILDREN (SPARKLE TRIAL): INITIAL SAFETY, PK, AND EFFICACY
A. Burke, Cambridge (UK)

CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR REFRACTORY AND RELAPSED BURKITT’S LYMPHOMA, EARLY RESPONSE IN PEDIATRIC PATIENTS
W. Q. Zhang, Beijing (China)

RESULTS FROM SINGLE AGENT TRIALS
Chair: C. Thieblemont, Paris (France)

PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
K. A. Rogers, Columbus, OH (USA)

RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB
S. D. Smith, Seattle, WA (USA)

A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
N. Kalakonda, Liverpool (UK)

TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
T. E. Witzig, Rochester, MN (USA)

DUVELISIB, AN ORAL DUAL PI3K-δ,γ INHIBITOR, EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) PERIPHERAL T-CELL LYMPHOMA: RATIONALE FOR THE PHASE 2 PRIMO TRIAL
S. M. Horwitz, New York, NY (USA)

EFFICACY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH LESS ADVANCED MYCOSIS FUNGOIDES: RESULTS FROM THE MAVORIC STUDY
J. Scarisbrick, Birmingham (UK)
Aula Magna
(USI Università)

Chair: J.M. Vose, Omaha, NE (USA)

17:05 OT01
NCRI PETReA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA
A.R. Pettitt, Liverpool (UK)

17:15 OT02
POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL
H. Tilly, Rouen (France)

17:25 OT03
PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R-CHOP VS PLACEBO/R-CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
J. Zhu, Beijing (China)

17:35 OT04
THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS
J.C. Villasboas, Rochester, MN (USA)

17:45 OT05
ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
T. Cummin, Southampton (UK)

17:55 OT06
TELOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA
P. Porcu, Philadelphia, PA (USA)
Thursday, June 20, 2019

08:00 – 08:45

MEET THE PROFESSOR SESSIONS
5 parallel sessions

Room A
EB10
THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
S. Rule, Plymouth (UK)

Room B
EB09
MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
S.V. Rajkumar, Rochester, MN (USA)

Cinema Corso
EB01
PCNSL, A CURABLE DISEASE
T.T. Batchelor, Boston, MA (USA)

Auditorium
EB11
LIQUID BIOPSY IN NON-HODGKIN’S LYMPHOMA
W.H. Wilson, Bethesda, MD (USA)

Aula Magna
EB04
NEW TREATMENT OPTIONS IN HAIRY CELL LEUKEMIA WITH FOCUS ON BRAF INHIBITORS
B. Falini, Perugia (Italy)
offered only once

09:00 – 17.00
Marquee

POSTER SESSION

09:00 – 10:30

“CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)
4 parallel sessions

Room A
DLBCL
Chair: L.H. Sehn, Vancouver, B.C. (Canada)
Discussants: E. Giné Soca, Barcelona vs J.R. Westin, Houston

Cinema Corso
HODGKIN LYMPHOMA
Chair: A.S. LaCasce, Boston, MA (USA)
Discussants: A.M. Sureda Balari, Barcelona vs H.J. Lee, Houston

Auditorium
RADIOThERAPY FOR LymphOmas
Chair: L. Specht, Copenhagen (Denmark)
Discussants: T. Illidge, Manchester (UK) vs B.S. Dabaja, Houston

Aula Magna
DIFFICULT PATHOLOGICAL CASES
Chair: M. Ghielmini, Bellinzona (Switzerland)
Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland) and P. Gaulard, Paris (France)
Discussants: A. Lopez-Guillermo, Barcelona vs R. Hagemeister, Houston

09:00 – 10:30
Abstract Nr
SESSION 1 – DLBCL: BIOLOGY
Co-chairs: R. Dalla-Favera, New York, NY (USA) and R. Küppers, Essen (Germany)

09:00
035
AN AUTOCHTHONOUS MOUSE MODEL OF MYD88 P.L265P- AND BCL2-DRIVEN DIFFUSE LARGE B CELL LYMPHOMA
G. Knittel, Cologne (Germany)

09:15
036
CRYPTIC MYC AND BCL2 REARRANGEMENTS ARE AMONG A RANGE OF GENETIC MECHANISMS UNDERLYING THE DOUBLE HIT SIGNATURE IN NON-DOUBLE HIT DIFFUSE LARGE B-CELL LYMPHOMA
L.K. Hilton, Burnaby, B.C. (Canada)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>FUNCTIONAL CHARACTERIZATION OF NFkBIZ 3' UTR MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA</td>
<td>S.E. Arthur, Burnaby, B.C. (Canada)</td>
</tr>
<tr>
<td>09:45</td>
<td>THE TRANSCRIPTION FACTOR FLI1 SUSTAINS RELEVANT BIOLOGICAL PATHWAYS AND DRIVES ONCOGENES THAT PROMOTE CELL GROWTH IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)</td>
<td>G. Sartori, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>10:00</td>
<td>TRANSCRIPTIONAL AND GENOMIC INTRA-TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA</td>
<td>T. Roider, Heidelberg (Germany)</td>
</tr>
<tr>
<td>10:15</td>
<td>THE NONCODING RNA GECPAR IS INVOLVED IN WNT SIGNALING AND HAS TUMOR-SUPPRESSOR ACTIVITY IN DIFFUSE LARGE B CELL LYMPHOMA</td>
<td>S. Napoli, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT</td>
<td>L. Ceriani, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>11:15</td>
<td>SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA</td>
<td>J.R. Westin, Houston, TX (USA)</td>
</tr>
<tr>
<td>11:30</td>
<td>RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY</td>
<td>P. Lugtenburg, Rotterdam (Netherlands)</td>
</tr>
<tr>
<td>11:45</td>
<td>IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A LARGE POPULATION-BASED STUDY</td>
<td>T. Shree, Stanford, CA (USA)</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>LUNCH TIME AND POSTER VIEWING</td>
<td>from 12:30 to 13:00 authors in front of their poster for discussion with attendees</td>
</tr>
<tr>
<td>13:00 – 13:45</td>
<td>GIANNI BONADONNA MEMORIAL LECTURE</td>
<td>sponsored by the American Association for Cancer Research – AACR</td>
</tr>
<tr>
<td></td>
<td>Room A, B, Marquee, Cinema Corso and Aula Magna (USI Università)</td>
<td>Laudatio: M.A. Shipp, Boston, MA (USA)</td>
</tr>
<tr>
<td></td>
<td>002 PRECISION EPIGENETIC THERAPY FOR B-CELL LYMPHOMA</td>
<td>A.M. Melnick, New York, NY (USA)</td>
</tr>
</tbody>
</table>
SESSION 3 – CLL

Chairs: J.F. Seymour, Melbourne (Australia) and M. Hallek, Cologne (Germany)

13:45 045 INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A)
A. Condoluci, Bellinzona (Switzerland)

14:00 046 FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES
K. Fischer, Cologne (Germany)

14:15 047 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY
E. Tausch, Ulm (Germany)

Best abstract submitted by a young investigator/travel grant recipient

14:30 048 ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB (IR) OR BENDAMUSTINE (BR) BY INVESTIGATOR CHOICE IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: PHASE 3 ASCEND STUDY
P. Ghia, Milan (Italy)

14:45 049 ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
W. Xu, Nanjing (China)

15:00 050 A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY
A.R. Mato, New York, NY (USA)

SESSION 4 – TREATMENT WITH NOVEL ANTIBODIES

Co-chairs: D.G. Maloney, Seattle, WA (USA) and P.L. Zinzani, Bologna (Italy)

15:40 051 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
R.H. Advani, Stanford, CA (USA)

15:55 052 CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
M.S. Topp, Würzburg (Germany)
CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
M.J. Dickinson, Melbourne (Australia)

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
J. Radford, Manchester (UK)

ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)
G. Collins, Oxford (UK)

SESSION 5 – T-CELL LYMPHOMAS
Co-chairs: S. Luminari, Reggio Emilia (Italy) and K.J. Savage, Vancouver, B.C. (Canada)

RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.
P. Ghione, New York, NY (USA)

AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY
M. Lopez-Parra, Salamanca (Spain)

FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY
O. Tournilhac, Clermont-Ferrand (France)

TREATMENT BENEFIT ASSOCIATING WITH NON-ANTHRACYCLINE CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE
S. Qi, Beijing (China)

SINTILIMAB FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL (ORIENT-4)
R. Tao, Shanghai (China)

“FOCUS ON…” SESSIONS
5 parallel sessions

CLL AND MORE
Chair: D. Rossi, Bellinzona (Switzerland)

FIVE-YEAR FOLLOW-UP OF FIRST-LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
A. Tedeschi, Milan (Italy)

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL
O. Al-Sawaf, Cologne (Germany)
IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY
J. Wu, San Francisco, CA (USA)

AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/REFRACTORY CLL
S. Handunnetti, Melbourne (Australia)

TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
T. Siddiqi, Duarte, CA (USA)

THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL
E. Tiacci, Perugia (Italy)

CHEMOTHERAPY-FREE STRATEGIES
Chair: J.W. Friedberg, Rochester, NY (USA)

PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY-FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK)
A. Moccia, Bellinzona (Switzerland)

EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL
F. Morschhauser, Lille (France)

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS
J.P. Leonard, New York, NY (USA)

INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
J. Sharman, Eugene, OR (USA)

RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSAN ANCILLARY STUDY
M.H. Delfau-Larue, Creteil (France)

SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS.
A. Stathis, Bellinzenza (Switzerland)

NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
Chair: A. Davies, Southampton (UK)

PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION
A.R. Mato, New York, NY (USA)
PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL
S.D. Smith, Seattle, WA (USA)

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
C.S. Tam, Melbourne (Australia)

A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW-GRADE B-CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS
T. Shree, Stanford, CA (USA)

EXTENDED FOLLOW-UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN RESEARCH GROUP (E4412)
C. Diefenbach, New York, NY (USA)

HIGH EXPRESSION OF BCL-2 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA CONFERS POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS.
T.E. Cummin, Southampton (UK)

FIRST-IN-CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN-HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY
Y. Liu, New York, NY (USA)

COPANLISIB AND VOLASERTIB OVERCOME IBRUTINIB-VENETOCLAX RESISTANCE VIA TARGETING PI3K-AKT SIGNALING AND G2/M CELL CYCLE TRANSITION IN MANTLE CELL LYMPHOMA
R. Zhang, Houston, TX (USA)

THE LANDSCAPE OF DRUG PERTUBATION EFFECTS IN LEUKEMIA AND LYMPHOMA
T. Zenz, Zurich (Switzerland)

DISCOVERY OF A NOVEL, POTENTIAL FIRST-IN-CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS
U. Philippar, Bersee (Belgium)

KYM-001, A FIRST-IN-CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88-MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION
J. Kelleher, Cambridge, MA (USA)

THE ANTIBODY-DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT-402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI-LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION
C. Tarantelli, Bellinzona (Switzerland)
HIGH RISK LARGE B-CELL LYMPHOMAS

Chair: L.H. Sehn, Vancouver, B.C. (Canada)

17:05  085  EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV-SPECIFIC CTL AND IBRUTINIB THERAPY
M.K. Gandhi, Brisbane (Australia)

17:15  086  YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS
S. Leppä, Helsinki (Finland)

17:25  087  SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R2-CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL
G.S. Nowakowski, Rochester, MN (USA)

17:35  088  INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE-ADJUSTED R-EPOCH FOR PATIENTS WITH RICHER'S SYNDROME (CRC-043)
M.S. Davids, Boston, MA (USA)

17:45  089  IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY
F. Morschhauser, Lille (France)

17:55  090  CD19-DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES
E.A. Chong, Philadelphia, PA (USA)
Friday, June 21, 2019

08:00 – 08:45  MEET THE PROFESSOR SESSIONS 📚
5 parallel sessions

Room A   EB05  HOW TO APPROACH CLL IN CLINICAL PRACTICE
M. Hallek, Cologne (Germany)

Room B   EB02  DOUBLE HIT LYMPHOMA, SO WHAT?
A. Davies, Southampton (UK)

Cinema Corso   EB06  CUTANEOUS LYMPHOMAS
W. Kempf, Zurich (Switzerland)

Auditorium   EB07  MANAGING THE TOXICITIES OF CAR T-CELL THERAPY
S.S. Neelapu, Houston, TX (USA)

Aula Magna   EB08  RARE B CELL LYMPHOMAS IN CHILDREN AND ADOLESCENTS
L. Quintanilla-Martinez de Fend, Tübingen (Germany) and
W. Wössmann, Hamburg (Germany)
offered only once

09:00 – 18:30  POSTER SESSION

09:00 – 10:30  “CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)
3 parallel sessions

Room A  FL/ INDOLENT LYMPHOMA
Chair: S. Rule, Plymouth (UK)
Discussants: M. Provencio Pulla, Madrid vs L.J. Nastoupil, Houston

Cinema Corso  CLL
Chair: S. O’Brien, Irvine, CA (USA)
Discussants: J. Delgado, Barcelona vs P.A. Thompson, Houston

Aula Magna   PTCL
(USI Università)  Chair: K.J. Savage, Vancouver, B.C. (Canada)
Discussants: A. Martin, Salamanca vs N.H. Fowler, Houston

09:00 – 10:30  SESSION 6 – LYMPHOMA PATHOLOGY
Room B and Marquee  Co-chairs: K. Ohshima, Kurume (Japan) and E. Campo, Barcelona (Spain)

09:00  091  DIAGNOSIS AND CLASSIFICATION ASSISTANCE FROM LYMPHOMA
MICROSCOPIC IMAGES USING DEEP LEARNING
P. Brousset, Toulouse (France)

09:15  092  INTEGRATING TUMOR- AND MICROENVIRONMENT-REFLECTING GENES IN A
UNIQUE AND ROUTINE-APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN
DLBCL.
S.A. Pileri, Milan (Italy)

09:30  093  CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION
PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE
3 PHOENIX TRIAL
S. Balasubramanian, San Diego CA (USA)
LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA

S. Araf, London (UK)

DEFINING BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION IN A SPECIALISED UK HAEMATOPATHOLOGY DIAGNOSTIC SERVICE

S. Barrans, Leeds (UK)

GENOME WIDE-ANALYSIS OF T(14;18)-NEGATIVE FOLLICULAR LYMPHOMA

L. Quintanilla-Martinez de Fend, Tübingen (Germany)

WORKSHOP – CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES

Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG open to all 15-ICML attendees

Part 1: FRACTIONATION ISSUES IN RADIOTHERAPY OF LYMPHOMAS

Chair: M.K. Gospodarowicz, Toronto, ON (Canada)

DOSE PER FRACTION, RESPONSE, LATE EFFECTS RELATIONSHIP IN LYMPHOMAS

R. Hoppe, Stanford, CA (USA)

OPTIMAL DOSE FRACTIONATION FOR INDOLENT AND AGGRESSIVE LYMPHOMAS

P. Hoskin, London and Manchester (UK)

OPTIMAL DOSE FRACTIONATION IN HODGKIN LYMPHOMAS

C. Baues, Cologne (Germany)

COFFEE BREAK inside Auditorium (USI Università), for attendees

Part 2: RADIOTHERAPY IN THE ELDERLY LYMPHOMA PATIENT

LYMPHOMA IN THE ELDERLY - SCOPE OF THE PROBLEMS

I. Glimelius, Uppsala (Sweden)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: INDOLENT LYMPHOMAS

U. Ricardi, Turin (Italy)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: AGGRESSIVE LYMPHOMA

J. Yahalom, New York, NY (USA)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: HODGKIN LYMPHOMA

L. Specht, Copenhagen (Denmark)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: LATE EFFECTS

D. Hodgson, Toronto, ON (Canada)

QUESTIONS

COFFEE BREAK

Marquee, Cinema Corso, USI Università
SESSION 7 – HODGKIN LYMPHOMA
Co-chairs: R.H. Advani, Stanford, CA (USA) and T.A. Lister, London (UK)

11:00 – 12:00
Room A, Marquee, Cinema Corso and Aula Magna (USI Università)

11:00 097 STAGE I-II NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA IN THE MODERN ERA: A MULTI-INSTITUTIONAL EXPERIENCE OF ADULT PATIENTS BY ILROG M.S. Binkley, Stanford, CA (USA)

11:15 098 NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP S. Ansell, Rochester, MN (USA)

11:30 099 CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL A. Gallamini, Nice (France)

11:45 100 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA A. Prica, Toronto, ON (Canada)

12:00 – 13:00
Marquee

LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45
Room A, B, Marquee, Cinema Corso and Aula Magna (USI Università)

JOHN ULTMANN MEMORIAL LECTURE 📖

sponsored by the European School of Oncology – ESO

Laudatio: J.M. Vose, Omaha, NE (USA)

THIRTY YEARS OF T-CELL LYMPHOMAS
P. Gaulard, Créteil (France)

13:45 – 15:00
4 parallel sessions

SESSION 8 – FOLLICULAR LYMPHOMA
Co-chairs: B.S. Kahl, St. Louis, MO (USA) and M. Herold, Erfurt (Germany)

13:45 101 PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY: A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL S. Dirnhofer, Basel (Switzerland)

14:00 102 DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY P. Perez Galan, Barcelona (Spain)

14:15 103 IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA C.L. Batlevi, New York, NY (USA)

14:30 104 RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI M. Federico, Modena (Italy)
14:45 105 INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
F. Morschhauser, Lille (France)

Room B and Marquee

SESSION 9 - EXTRANODAL LYMPHOMAS
Co-chairs: M.K. Gospodarowicz, Toronto, ON (Canada) and E. Zucca, Bellinzona (Switzerland)

13:45 106 INTEGRATIVE GENOMIC ANALYSIS IDENTIFIES KEY PATHOGENIC CONCEPTS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
A. Mottok, Ulm (Germany)

14:00 107 OUTCOME OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET-GUIDED APPROACH
A. Hayden, Vancouver, B.C. (Canada)

14:15 108 NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY
P.L. Zinzani, Bologna (Italy)

14:30 109 R-CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL
A.J. Ferreri, Milan (Italy)

14:45 110 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER SOLID ORGAN TRANSPLANT (SOT): SURVIVAL AND PROGNOSTICATION AMONG 570 PATIENTS (PTS) TREATED IN THE MODERN ERA
D. Jagadeesh, Cleveland, OH (USA)

14:15 – 17:30 Auditorium (USI Università)

IBSA FOUNDATION SPECIAL FORUM - REVOLUTIONARY THERAPIES FOR CANCER
Chairmen: F. Cavalli, Bellinzona (Switzerland) and A. Alimonti, Bellinzona (Switzerland)
Organized by IBSA Foundation for Scientific Research
Open to all 15-ICML attendees, appreciated pre-registration at www.ibsafoundation.org (free session)

14:15 WELCOME AND INTRODUCTION
S. Misiti, IBSA Foundation
A. Alimonti, IBSA Foundation Scientific Board

14:30 mTOR SIGNALING IN GROWTH AND METABOLISM
M. Hall, Basel (Switzerland)

15:00 INNATE IMMUNITY, INFLAMMATION AND CANCER: FROM BENCH TO BEDSIDE
A. Mantovani, Milan (Italy), London (UK)

15:30 BUILDING NEXT GENERATION CAR T CELLS
C.H. June, Philadelphia, PA (USA)

16:00 FROM MOLECULAR ADDICTION TO IMMUNE ACTIVATION: REINVENTING THERAPIES FOR CANCER
S. Peters, Lausanne (Switzerland)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Workshop</th>
<th>Details</th>
</tr>
</thead>
</table>
| 14:15 – 17:15 | **UCLI-ICML JOINT SESSION – NEW DATA ON T-CELL AND OTHER LYMPHOMAS**           | Honorary Presidents: F. Cavalli, Bellinzona (Switzerland) and J. Ma, Harbin (China)  
Executive Presidents: W.J. Chng, Singapore (Singapore), J. M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China) |
| 14:20      | 20-YEAR SURVIVAL DATA ANALYSIS OF PTCL PATIENTS IN PEKING UNIVERSITY CANCER HOSPITAL | Y. Song, Beijing (China)                                                  |
| 14:45      | DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PTCL: LEVERAGING A LOGIC FOR PD1/PDL-1 INHIBITORS | O.A. O’Connor, New York, NY (USA)                                        |
| 15:10      | CLINICAL OUTCOME OF AN PROSPECTIVE, MULTICENTRE, RANDOMIZED, PHASE III NON-INFERIORITY CLINICAL TRIAL FOR PATIENTS WITH EXTRANODAL NK/T CELL LYMPHOMA TREATED BY P-GEMOX OR ASPAMETDEX | H. Huang, Guangzhou (China)                                               |
| 15:35 – 15:55 | **COFFEE BREAK inside Aula Magna (USI Università), for attendees**             |                                                                         |
| 15:55      | 114 NEW DATA IN THE MOLECULAR PATHOLOGY OF T CELL LYMPHOMAS                    | L. de Leval, Lausanne (Switzerland)                                       |
| 16:20      | 115 DIFFUSE LARGE B-CELL LYMPHOMA: USING IMMUNE BIOMARKERS TO DEFINE NOVEL THERAPIES | W. Zhao, Shanghai (China)                                                |
| 16:45      | 116 THE RELEVANCE OF OBSERVATIONAL REGISTRIES: THE CASE OF T CELL LYMPHOMA PROJECTS 1.0 AND 2.0 | M. Federico, Modena (Italy)                                              |
| 15:00 – 15:30 | **COFFEE BREAK**                                                                |                                                                         |
| 15:30 – 15:45 | **REPORT OF THE 15-ICML WORKSHOP**                                             |                                                                         |
| Room A, B, Marquee and Cinema Corso | Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France) | BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE W.H. Wilson, Bethesda, MD (USA) |
| 15:45 – 17:15 | **SESSION 10 – ADVANCES IN CAR-T CELL TREATMENT**                              |                                                                         |
| Room A, B, Marquee and Cinema Corso | Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France) | NOVEL BAFF-R CAR T-CELL THERAPY FOR CD19 ANTIGEN-LOSS RELAPSED B CELL TUMORS L.W. Kwak, Duarte, CA (USA)  
PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION C.L. Batlevi, New York, NY (USA)  
CD30-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL) C.A. Ramos, Houston, TX (USA) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>120</td>
<td>DURABLE RESPONSES AFTER CD19-TARGETED CAR-T CELL IMMUNOTHERAPY WITH CONCURRENT IBRUTINIB FOR CLL AFTER PRIOR IBRUTINIB FAILURE</td>
<td>J. Gauthier, Seattle, WA (USA)</td>
</tr>
<tr>
<td>16:45</td>
<td>121</td>
<td>HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR-T CELL IMMUNOTHERAPY</td>
<td>A.V. Hirayama, Seattle, WA (USA)</td>
</tr>
<tr>
<td>17:00</td>
<td>122</td>
<td>SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY</td>
<td>T. Siddiqi, Duarte, CA (USA)</td>
</tr>
<tr>
<td>17:15 – 17:35</td>
<td>Room A, B, Marquee and Cinema Corso</td>
<td>SPECIAL LECTURE</td>
<td>Chair: F. Cavalli, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>17:35 – 18:30</td>
<td>Marquee</td>
<td>FAREWELL APERO</td>
<td></td>
</tr>
</tbody>
</table>
Saturday, June 22, 2019

08:30 – 10:30
Auditorium (USI Università)
ESO – ESmit Educational Session - PET-CT IN LYMPHOMA
Chair: A.T. Lister, London (UK)
Organized by the European School of Oncology – ESO and the European School of Multimodality Imaging & Therapy – ESmit
Open to all 15 ICML attendees

08:30
HOW TO INTERPRET PET-CT SCANS IN LYMPHOMAS: VISUAL AND FUNCTIONAL EVALUATION
M. Meignan, Creteil (France)

08:50
PET-BASED CLINICAL DECISIONS: WHERE DO WE STAND AND WHERE WE MAY GO
P. W. M. Johnson, Southampton (UK)

09:20
THE LUGANO CLASSIFICATION 5 YEARS AFTER: SHOULD WE CHANGE ANYTHING?
B. D. Cheson, Washington, D.C. (USA)

09:40
CHALLENGING CASES FROM THE ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
Presented by E. Zucca, Bellinzona (Switzerland) and L. Ceriani, Bellinzona (Switzerland)
Discussants: A. T. Lister, London (UK) and all faculty

08:30 – 10:00
Session 11 – New Drug Combinations
Room A and B
Co-chairs: A. Younes, New York, NY (USA) and M. Dreyling, Munich (Germany)

08:30
124
PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND)
G. Salles, Lyon (France)

08:45
125
BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA
M. Dickinson, Melbourne (Australia)

09:00
126
POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS
A. McMillan, Nottingham (UK)

09:15
127
THE PI3KΔ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)
A. D. Zelenetz, New York, NY (USA)

09:30
128
INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE
S. M. Ansell, Rochester, MN (USA)

09:45
129
TARGETING THE PERIPHERAL T-CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5-AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL-MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY
L. Falchi, New York, NY (USA)
10:15 – 11:15  "FOCUS ON" SESSION - INDOLENT NON-FOLLICULAR LYMPHOMA
Room A and B
Chair: G.S. Nowakowski, Rochester, MN (USA)

10:15    130  EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT
A. Conconi, Ponderano (Italy)

10:25    131  INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE "IRIS" TRIAL
A.J. Ferreri, Milan (Italy)

10:35    132  MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY
A. Bruscaggin, Bellinzona (Switzerland)

10:45    133  UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY
P.L. Zinzani, Bologna (Italy)

10:55    134  IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY
J. Castillo, Boston, MA (USA)

11:05    135  IBRUTINIB MONOTHERAPY PRODUCES LONG-TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM’S MACROGLOBULINEMIA: FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821)
S.P. Treon, Boston, MA (USA)

11:15 – 11:40  15-ICML HIGHLIGHTS  
Room A and B
“TAKE HOME MESSAGES”
J.W. Friedberg, Rochester, NY (USA)

11:40 – 11:50  CLOSURE AND FAREWELL
F. Cavalli, Bellinzona (Switzerland)

13:30 – 18:00  IV INTERNATIONAL WORKSHOP ON CANINE LYMPHOMA - HOW TO STAGE CANINE LYMPHOMA IN 2019
Room B
Co-chairs: L. Aresu, Turin (Italy), S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy)
Organized by the European Canine Lymphoma Network
go to all 15-ICML attendees

- Updated on May 22, 2019 -